Alembic Pharma Vadodara facility concludes USFDA inspection with zero observations
Vadodara: Alembic Pharma has recently announced that the Company has successfully completed the United States Food and Drug Administration (USFDA) inspection for its Bioequivalence Facility located at Vadodara without any observations.
The inspection was conducted from 17th October 2022 to 21st October 2022.
Read also: Alembic Pharma gets USFDA nod for cancer injection Paclitaxel
Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company headquartered in Gujarat. It is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities. Products under International Generics are manufactured across our world-class facilities in Panelav, Karkhadi, and Jarod in Gujarat. Under this vertical, the company also has R&D facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (USA).
Read also: Alembic Pharma gets USFDA nod for cancer injection Paclitaxel
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.